Answers are grounded in this paper and cite their sources.
While solute carrier family 10 member 3 (SLC10A3) is an oncogene in numerous malignancies, its involvement in liver cancer (LC) progression is not yet well understood. In the present study, western blot (WB) analysis demonstrated elevated SLC10A3 expression in LC cell lines compared with normal liver cell lines. Small interfering RNA was used to knockdown SLC10A3 expression in these cell lines, and transcriptome sequencing was performed on the suppression and control groups to determine the differentially expressed genes (DEGs) and main signaling pathways affected by SLC10A3. Kyoto Encyclopedia of Genes and Genomes analysis illustrated significant enrichment of these DEGs in the transforming growth factor‑β (TGF‑β) pathway in LC cell lines (P<0.05). WB analysis illustrated that SLC10A3 knockdown suppressed TGF‑β pathway signaling, reversing epithelial‑mesenchymal transition in LC cells. The biological effects of SLC10A3 knockdown were evaluated using colony formation, 5‑ethynyl‑2'‑deoxyuridine, Cell Counting Kit‑8, wound healing and Transwell invasion assays. The findings indicated that reducing SLC10A3 expression markedly hindered LC cell aggressiveness (P<0.05). Rescue assays were ultimately performed to confirm the observed regulatory mechanisms. The present study found that SLC10A3 was upregulated in LC cells, and its knockdown suppressed cell migration and invasion, which is associated with the TGF‑β pathway, illustrating its potential as a target for LC treatment.
No takes yet. Share an insight, caveat, or question.
Long et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: